The Filing Desk

Arcturus Therapeutics

ARCT · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

ARCT · Last close · November 19, 2026
$7.60
Value Arcturus Therapeutics yourself

Arcturus Therapeutics' revenue fell 46.1% to $82 million in fiscal 2025. Its operating margin was −93.0%, down from −62.8% a year earlier. Free cash flow was −$74 million. The diluted share count rose 1.4%.

ARCTURUS THERAPEUTICS HOLDINGS INC. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001193125-26-088391 Updated
Revenue
$82M
46.1%
Operating margin
−93.0%
30.1 pts
Net income
−$66M
 
Free cash flow
−$74M
 
Return on equity
−28.9%
2.2 pts
Market cap
$216M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Arcturus Therapeutics does

Arcturus Therapeutics develops medicines and vaccines based on messenger RNA (mRNA), the molecule that tells cells how to make a protein. It focuses on rare diseases of the liver and lungs, and it also has vaccines for infectious diseases. It uses its own technologies: STARR, a self-amplifying mRNA platform, and LUNAR, a fat-based particle system that delivers RNA to the target tissue.

Its internal programs are in Phase 2 trials for ornithine transcarbamylase (OTC) deficiency, a rare liver disorder, and for cystic fibrosis. It developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine approved in Japan, the European Union and the United Kingdom. It sells the vaccine through its partner CSL Seqirus, part of CSL Limited, and sales began in Japan in October 2024.

CSL Seqirus also works with Arcturus on mRNA vaccines for influenza and three other infectious diseases. The 10-K notes that CSL reported an accounting write-down on this collaboration in February 2026, citing declining COVID-19 disease burden and tougher U.S. regulatory requirements.

Its biggest risks, as it describes them

  • A history of significant losses, and a need to raise more capital that may not be available.
  • It depends heavily on its relationship with CSL Seqirus for its vaccines.
  • It relies on collaboration partners, whose relationships could fail.
  • It relies on contract makers and research organizations to produce and test its candidates.
From Arcturus Therapeutics's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Arcturus Therapeutics lost money in fiscal 2025: a net loss of $66 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments370392292237231
Debt incl. finance leases15————
Net debt (negative means net cash)−355————
Net debt to EBITDA—————
Debt to equity0.1x————
Interest coverage−296.6x15.0x−36.8x——
Current ratio3.8x3.2x4.7x4.7x6.6x
Quick ratio3.8x3.2x4.7x4.7x6.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Arcturus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Arcturus Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−31.6%−48.3%−137.0%
Altman Z''2.570.920.81
Accruals ratio−2.6%−5.5%2.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't risePassFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Arcturus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Arcturus TherapeuticsFY25−46.1%−93.0%−90.8%———
Nurix TherapeuticsFY2554.0%−340.2%−313.7%———Compare
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
ARS PharmaceuticalsFY25−5.5%−212.9%−203.1%——2Compare
Assembly BiosciencesFY25153.5%−16.8%−56.9%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1621101220616715282
Revenue growth—32.0%−54.1%29.6%1,566.8%−19.0%−8.7%−46.1%
Gross profit————————
Research and development173458174148192195112
Operating income−22−26−72−20312−78−96−76
Net income−22−26−72−2049−30−81−66
Diluted EPS (US$)−2.16−2.15−3.55−7.740.35−1.12−3.00−2.40
Diluted shares (millions)1012202627272727
Cash flow
Cash from operations−21−6−43−13532−18−60−74
Capital expenditure21238310
Free cash flow−22−7−45−13824−21−60−74
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation1272931353825
Balance sheet at fiscal year end
Cash and short-term investments3771463370392292237231
Debt incl. finance leases10151515————
Total assets4482476393450429344271
Total liabilities31568016518015110357
Shareholders' equity1426397228270278241214
Margins and ratios
Gross margin————————
Operating margin−138.5%−122.7%−749.8%−1,641.3%5.9%−46.9%−62.8%−93.0%
Net margin−138.3%−125.0%−756.4%−1,648.0%4.5%−17.8%−53.1%−80.2%
Free cash flow margin−141.2%−34.9%−467.6%−1,120.2%11.8%−12.6%−39.6%−90.8%
Rule of 40 (growth + FCF margin)—−3.0%−521.7%−1,090.7%1,578.6%−31.6%−48.3%−137.0%
Return on capital————————
Return on equity—−131.8%−34.2%−65.2%3.8%−10.8%−31.2%−28.9%
Return on assets—−41.1%−25.8%−46.9%2.2%−6.8%−20.9%−21.4%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Arcturus Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Arcturus Therapeutics.